Traders should monitor the June 2026 data readout from the first cohort of the RESOLUTION trial as a key catalyst; positive translational and clinical data could drive significant upside given the high unmet need in autoimmune diseases and ALLO-329’s potential to become a scalable, off-the-shelf therapy.
Price Chart
Executive Summary
Allogene Therapeutics announced pre-clinical data published in Nature Communications showing that its dual-targeting ALLO-329 CAR T cell therapy, leveraging its Dagger® technology, demonstrated robust expansion and persistence in models of autoimmune disease by targeting both CD19+ B cells and CD70+ activated T cells. The Phase 1 RESOLUTION trial is actively enrolling, with initial data expected June 2026 and a further update anticipated by year-end.
Key Facts
- Pre-clinical data for ALLO-329 published in Nature Communications demonstrate dual targeting of CD19+ B cells and CD70+ T cells with enhanced CAR T cell expansion and persistence.
- ALLO-329 incorporates CRISPR-based dual CAR expression and Allogene’s Dagger® technology to potentially eliminate the need for cytotoxic lymphodepletion.
- Phase 1 RESOLUTION trial is a 3+3 dose-escalation study across autoimmune indications including lupus, scleroderma, and myositis, with dosing as low as 20 million CAR T cells.
- Initial clinical data from the first cohort expected June 2026; additional update planned for year-end 2026.
- ALLO-329 received three FDA Fast Track Designations in April 2025 for lupus, myositis, and scleroderma.
Financial Impact
No immediate financial impact; potential long-term commercial significance if clinical trials succeed.
Risk Factors
- Pre-clinical results may not translate to clinical efficacy in humans.
- Clinical trial enrollment or safety issues could delay development.
- Fast Track Designation does not guarantee faster approval or eventual regulatory success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3274436 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 144 | $1.25 $1.25 | · 0.00% | ▲ +0.52% | $1.21 (−3.20%) |
Sep 2, 2026 7w ago | 8-K | $1.98 $1.98 | · 0.00% | ▼ −1.05% | $1.21 (−38.89%) |
Aug 21, 2026 9w ago | 144 | $2.03 $2.17 | ▲ +6.90% | ▲ +6.58% | $1.21 (−40.39%) |
Aug 21, 2026 9w ago | EFFECT | $2.09 $2.03 | ▲ +2.87% | ▲ +2.58% | $1.21 (+42.11%) |
Aug 6, 2026 11w ago | Institutional Cluster | $1.97 $2.01 | ▲ +2.03% | ▲ +1.42% | $1.21 (−38.58%) |
Jun 22, 2026 18w ago | 8-K | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.21 (+41.55%) |
Jun 22, 2026 18w ago | 424B5 | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.21 (+41.55%) |
May 28, 2026 21w ago | DEFA14A | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.21 (−44.24%) |
May 28, 2026 21w ago | 8-K | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.21 (−44.24%) |
May 28, 2026 21w ago | Press Release | $2.17 $2.15 | ▼ −0.92% | ▼ −1.20% | $1.21 (−44.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers